ARO-HSD
ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease.[1][2][3][4] The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.[5]
References[edit]
- ^ Mak, Lung-Yi; Gane, Ed; Schwabe, Christian; Yoon, Ki Tae; Heo, Jeong; Scott, Russell; Lee, Jeong-Hoon; Lee, Jung Il; Kweon, Young Oh; Weltman, Martin; Harrison, Stephen A.; Neuschwander-Tetri, Brent A.; Cusi, Kenneth; Loomba, Rohit; Given, Bruce D.; Christianson, Dawn R.; Garcia-Medel, Eric; Yi, Min; Hamilton, James; Yuen, Man-Fung (April 2023). "A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis". Journal of Hepatology. 78 (4): 684–692. doi:10.1016/j.jhep.2022.11.025. PMID 36513186. S2CID 254561720.
- ^ Smati, Sarra; Canivet, Clémence M.; Boursier, Jérôme; Cariou, Bertrand (May 2023). "Voies thérapeutiques dans l'hépatopathie stéatosique métabolique". Médecine des Maladies Métaboliques. 17 (3): 261–270. doi:10.1016/j.mmm.2023.03.007. S2CID 257839829.
- ^ Ajmera, Veeral; Loomba, Rohit (May 2023). "Advances in the genetics of nonalcoholic fatty liver disease". Current Opinion in Gastroenterology. 39 (3): 150–155. doi:10.1097/MOG.0000000000000927. PMC 10167543. PMID 37144531.
- ^ Lindén, Daniel; Romeo, Stefano (October 2023). "Therapeutic opportunities for the treatment of NASH with genetically validated targets". Journal of Hepatology. 79 (4): 1056–1064. doi:10.1016/j.jhep.2023.05.007. PMID 37207913. S2CID 258777103.
- ^ Dealmakers, Biopharma (1 June 2022). "Buy buy RNAi". Biopharma Dealmakers. doi:10.1038/d43747-022-00169-4. Retrieved 3 December 2023.